Sagimet Biosciences Inc.: Sagimet Biosciences Announces Presentation of Additional Phase 2 Data on Denifanstat Identifying a Predictive Metabolic Signature in NASH Patients at EASL's International Liver Congress (ILC) 2022

Sagimet Biosciences, a clinical-stage biotechnology company focused on developing a portfolio of internally discovered, selective fatty acid synthase (FASN) inhibitors, announced today that it will present

Related Keywords

China ,California ,United States ,San Diego ,London ,City Of ,United Kingdom ,Kostenloser Wertpapierhandel ,Sagimet Biosciences ,Susan Kinkead ,Rohit Loomba ,University Of California ,Sagimet Biosciences Inc ,Research Center ,International Liver Congress ,European Association ,Sagimet ,Iosciences ,Nnounces ,Presentation ,Dditional ,Hase ,Data ,Denifanstat ,Identifying ,Predictive ,Etabolic ,Signature ,Cash ,Patients ,Asl ,Nternational ,Liver ,Congress ,022 ,